



TRANSGENOMIC[®]
the power of discovery

Transgenomic Stock to be Available for Trading under Blue Sky Laws

OMAHA, Neb. (June 30, 2010) – Transgenomic, Inc. (OTC/BB: TBIO) today announced that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Transgenomic will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in up to 38 states under their Blue Sky Laws.

Craig Tuttle, president and chief executive officer said, “We are pleased that Transgenomic stock may now be eligible for trading under a majority of States’ ‘Blue Sky’ laws and we intend to file for this eligibility with as many states as is practicable. Our goal is to improve awareness of the company among investors.”

The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at www.advisorinsight.com.

Company information distributed through the Market Access Program is based upon information that Standard & Poor’s considers to be reliable, but neither Standard & Poor’s nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE[®] Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR[®] Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular

Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Transgenomic, Inc.
Summary Financial Results
Unaudited Condensed Consolidated Statements of Operations
(dollars in thousands except per share data)

	Three Months Ended	
	March 31,	
	2010	2009
NET SALES	\$ 5,442	\$ 4,989
COST OF GOODS SOLD	<u>2,558</u>	<u>2,176</u>
Gross profit	2,884	2,813
OPERATING EXPENSES:		
Selling, general and administrative	2,432	2,975
Research and development	<u>827</u>	<u>844</u>
	<u>3,259</u>	<u>3,819</u>
LOSS FROM OPERATIONS	(375)	(1,006)
OTHER INCOME:		
Interest income	1	12
Other, net	<u>(1)</u>	<u>—</u>
	<u>—</u>	<u>12</u>
LOSS BEFORE INCOME TAXES	(375)	(994)
INCOME TAX BENEFIT	<u>(51)</u>	<u>(41)</u>
NET LOSS	<u>(324)</u>	<u>(953)</u>
BASIC AND DILUTED LOSS PER SHARE	\$ (0.01)	\$ (0.02)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	49,189,672	49,189,672

Transgenomic, Inc.
Summary Financial Results
Unaudited Condensed Consolidated Statements of Cash Flows
(dollars in thousands)

	Three Months Ended	
	March 31,	
	2010	2009
NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES	\$ 392	\$ 299
NET CASH FLOWS USED IN INVESTING ACTIVITIES	(47)	(214)
EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH	(89)	(11)
NET CHANGE IN CASH AND CASH EQUIVALENTS	256	74
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	5,642	4,771
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 5,898	\$ 4,845

Transgenomic, Inc.
Summary Financial Results
Unaudited Condensed Consolidated Balance Sheets
(dollars in thousands)

	March 31,	December 31,
	<u>2010</u>	<u>2009</u>
	(Unaudited)	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 5,898	\$ 5,642
Accounts receivable (net of allowances for bad debts of \$279 and \$310, respectively)	4,461	4,522
Inventories (net of allowance for obsolescence of \$478 and \$507, respectively)	3,494	3,552
Prepaid expenses and other current assets	944	738
Total current assets	14,797	14,454
PROPERTY AND EQUIPMENT, NET	894	967
OTHER ASSETS:		
Other assets (net of accumulated amortization of \$542 and \$525, respectively)	526	583
	<u>\$16,217</u>	<u>\$16,004</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	\$ 1,231	\$ 1,013
Other accrued expenses	3,019	2,517
Accrued compensation	655	573
Total current liabilities	4,905	4,103
Other long term liabilities	162	239
Total liabilities	5,067	4,342
STOCKHOLDERS' EQUITY	<u>11,150</u>	<u>11,662</u>
	<u>\$ 16,217</u>	<u>\$ 16,004</u>